Russell Investments Group
NBIX icon

Russell Investments Group’s Neurocrine Biosciences NBIX Stock Holding History

Russell Investments Group’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$55.5M Buy
329,065
+109,310
+50% +$16.2M 0.05% 371
2026
Q1 		$28.9M Buy
219,755
+94,952
+76% +$12.6M 0.03% 520
2025
Q4 		$17.7M Buy
124,803
+12,881
+12% +$1.87M 0.02% 674
2025
Q3 		$15.7M Buy
111,922
+27,753
+33% +$3.76M 0.02% 723
2025
Q2 		$10.6M Sell
84,169
-16,429
-16% -$1.88M 0.01% 831
2025
Q1 		$11.1M Sell
100,598
-25,619
-20% -$3.25M 0.02% 781
2024
Q4 		$17.2M Sell
126,217
-84,560
-40% -$10.5M 0.02% 632
2024
Q3 		$24.3M Sell
210,777
-77,984
-27% -$10.7M 0.04% 508
2024
Q2 		$39.7M Sell
288,761
-60,556
-17% -$8.3M 0.06% 319
2024
Q1 		$48.2M Sell
349,317
-55,962
-14% -$7.64M 0.08% 293
2023
Q4 		$53.4M Sell
405,279
-8,564
-2% -$986K 0.1% 234
2023
Q3 		$46.6M Buy
413,843
+13,479
+3% +$1.42M 0.09% 247
2023
Q2 		$37.8M Buy
400,364
+57,582
+17% +$5.63M 0.07% 300
2023
Q1 		$34.7M Buy
342,782
+186,397
+119% +$19.4M 0.07% 347
2022
Q4 		$18.7M Buy
156,385
+34,048
+28% +$3.99M 0.04% 533
2022
Q3 		$13M Sell
122,337
-29,963
-20% -$3.04M 0.03% 649
2022
Q2 		$14.8M Buy
152,300
+11,814
+8% +$1.09M 0.03% 612
2022
Q1 		$13.2M Buy
140,486
+89,615
+176% +$7.59M 0.02% 714
2021
Q4 		$4.33M Buy
50,871
+16,648
+49% +$1.53M 0.01% 1340
2021
Q3 		$3.28M Buy
34,223
+12,369
+57% +$1.17M 0.01% 1507
2021
Q2 		$2.13M Buy
21,854
+4,753
+28% +$456K ﹤0.01% 1876
2021
Q1 		$1.66M Buy
17,101
+3,070
+22% +$322K ﹤0.01% 1984
2020
Q4 		$1.34M Sell
14,031
-6,390
-31% -$617K ﹤0.01% 1970
2020
Q3 		$1.97M Sell
20,421
-58,844
-74% -$6.81M ﹤0.01% 1700
2020
Q2 		$9.67M Sell
79,265
-29,164
-27% -$3.22M 0.02% 749
2020
Q1 		$9.39M Buy
108,429
+35,475
+49% +$3.47M 0.02% 679
2019
Q4 		$7.84M Buy
72,954
+1,605
+2% +$168K 0.01% 959
2019
Q3 		$6.43M Sell
71,349
-138
-0.2% -$12.9K 0.01% 1071
2019
Q2 		$6.04M Buy
71,487
+694
+1% +$57K 0.01% 1133
2019
Q1 		$6.24M Buy
70,793
+1,084
+2% +$90.6K 0.01% 1121
2018
Q4 		$4.98M Sell
69,709
-36,844
-35% -$3.53M 0.01% 1149
2018
Q3 		$13.1M Sell
106,553
-13,059
-11% -$1.48M 0.02% 792
2018
Q2 		$11.7M Buy
119,612
+46,978
+65% +$4.21M 0.02% 813
2018
Q1 		$6.02M Buy
72,634
+7,567
+12% +$639K 0.01% 1252
2017
Q4 		$4.91M Buy
65,067
+37,192
+133% +$2.54M 0.01% 1365
2017
Q3 		$1.71M Buy
27,875
+19,518
+234% +$1.03M ﹤0.01% 1879
2017
Q2 		$384K Sell
8,357
-16,301
-66% -$791K ﹤0.01% 2513
2017
Q1 		$1.07M Sell
24,658
-2,391
-9% -$102K ﹤0.01% 2064
2016
Q4 		$1.02M Buy
+27,049
New +$1.22M ﹤0.01% 2162

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Fiera Capital (Canada)
Fiera Capital (Canada) Montreal, Quebec, Canada $27.6B AUM 23.56% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
Nordea Investment Management
Nordea Investment Management Stockholm, Sweden $123B AUM 38.85% 1-Year Est. Return
SCP
Seizert Capital Partners Birmingham, Michigan $2.42B AUM 22.12% 1-Year Est. Return

Russell Investments Group's NBIX Position: Q2 2026 in Review

Russell Investments Group increased its Neurocrine Biosciences (NBIX) stake by 50% in Q2 2026, buying an estimated $16.2M and bringing the position to 329,065 shares worth $55.5M. The position accounts for 0.05% of the portfolio, ranked #371.

Russell Investments Group first reported a position in NBIX in Q4 2016 and has held it in 39 quarters since. 388 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Russell Investments Group held 329,065 shares of Neurocrine Biosciences worth $55.5M as of Q2 2026.
  • Russell Investments Group bought 109,310 Neurocrine Biosciences shares in Q2 2026, an estimated $16.2M.
  • Neurocrine Biosciences made up 0.05% of Russell Investments Group's portfolio in Q2 2026, its #371 holding.
  • Russell Investments Group first reported a position in Neurocrine Biosciences in Q4 2016 and has held it in 39 quarters since.
  • 388 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Russell Investments Group's 13F filing for Q2 2026, filed 6 Aug 2026.